Changes in metalloproteinases in healthy normotensive patients with high-normal blood pressure

European Cytokine Network

Volumn 16, Issue 3, 2005, Pages 211-214

  Papadopoulos, Dimitrios P ^a   Makris, Thomas K ^a   Krespi, Panagiota G ^a   Poulakou, Maria ^b   Papazachou, Ourania G ^a   Hatzizacharias, Antonios N ^a   Perrea, Despina ^b   Votteas, Vasilios ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

High normal blood pressure; Metalloproteinases MMP 9; TIMP 1; TIMP 4

Indexed keywords

COLLAGEN; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE-4;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BODY MASS; COLLAGEN DEGRADATION; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; BLOOD; MIDDLE AGED;

BLOOD PRESSURE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 33644664088     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291.
2. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145.
3. Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens 2003; 21: 1627.
4. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491.
5. European Society of Hypertension-European Society of Cardiology. Guidelines Committee 2003 for the management of arterial hypertension. J Hypertens 2003; 21: 1011.
6. Seidell JC, Cigolini M, Deslypere JP, et al. Body fat distribution in relation to physical activity and smoking habits in 38 year-old European men. Am J Epidemiol 1991; 133: 257.
7. Varan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291.
8. Nagase H, Brew K. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem Soc Symp 2003; 70: 201.
9. Nagase H, Brew K. Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res 2002; 4(Suppl 3): S51.
10. Tayebjee MH, MacFadyen RJ, Lip GY. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J Hypertens 2003; 21: 2211.
11. Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375.
12. Leco KJ, Apte SS, Taniguchi GT, et al. Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997; 401: 213.
13. Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27: 1281.
14. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998; 98: 1728.
15. Rouet-Benzineb P, Buhler JM, Dreyfus P, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1999; 1: 337.
16. Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535.
17. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136.
18. Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17: 119.
19. Li-Saw-Hee FL, Edmunds E, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000; 75: 43.
20. Tayebjee MH, Nadar S, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17: 764.
21. Tayebjee MH, Karalis I, Nadar SK, et al. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension. Am J Hypertens 2005; 18: 325.
22. Tayebjee MH, Lim HS, MacFadyen RJ, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy. Diabetes Care 2004; 27: 2049.
23. Mujumdar VS, Tyagi SC. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens 1999; 17: 261.
24. Li H, Simon H, Bocan TM, et al. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 2000; 46: 298.
25. Camp TM, Smiley LM, Hayden MR, et al. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens 2003; 21: 1719.
26. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863.